UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): June 9, 2016

MEDICINOVA, INC.

(Exact name of Registrant as Specified in Its Charter)

DELAWARE(State or Other Jurisdiction of Incorporation)

001-33185

(Commission File Number)

33-0927979 (IRS Employer Identification No.)

4275 EXECUTIVE SQUARE, SUITE 650, LA JOLLA, CA (Address of Principal Executive Offices)

92037 (Zip Code)

Registrant's Telephone Number, Including Area Code: (858) 373-1500

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

k the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following sions (see General Instructions A.2. below):
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.07 Submission of Matters to a Vote of Security Holders.

MediciNova, Inc. (the "Company") held its 2016 annual meeting of stockholders on June 9, 2016 (the "Annual Meeting"). Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

(a) To elect two Class III Director nominees named below to serve until the 2019 Annual Meeting of Stockholders. The named nominees were so elected, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

Nominee	For	Withheld	Broker Non-Vote
Yutaka Kobayashi	15,311,494	169,727	2,445,837
Yoshio Ishizaka	15,325,144	156,077	2,445,837

(b) To ratify the selection by the Audit Committee of the Company's Board of Directors of BDO USA, LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2016. This proposal was approved, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

For	Against	Abstain	Broker Non-Vote
17,659,607	74,741	192,710	0

(c) To approve, on an advisory basis, the compensation of the Company's named executive officers. This proposal was approved, with the votes thereon at the Annual Meeting as follows:

Final Voting Results

For	Against	Abstain	Broker Non-Vote
14,762,866	601,313	117,142	2,445,737

SIGNATURES

Pursuant to the requirements of the Securities Exchange A thereunto duly authorized.	ant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned unto duly authorized.			
	MediciNova, Inc.			
Date: June 13, 2016	By:	/s/ Ryan Selhorn		
		Ryan Selhorn Chief Financial Officer		